NeuroSense Therapeutics Says As Of August 20, 2025, ~20% Of People With ALS From The Company's Phase 2a Study, Including Those Continuing Under Compassionate Use, Remain On Primec For More Than 5.5 Years, Having Lived With Als For Over 7 Years; Across These Multi-Year Exposures, Treatment Remains Well Tolerated, With No New Safety Signals Observed To Date
Benzinga Newsdesk 1 year ago
NewsGeneral
Full article content is not available on this page. Continue to benzinga.com to read the original report.
